内部人员在Taysha Gene 治疗库存中出售了1.8亿多美元,继续损失,并呈下降趋势。 Insider sold over $1.8M in Taysha Gene Therapies stock amid continued losses and downward trend.

内线Sukumar Nagendran在2025年9月至12月期间出售了37万多股Taysha基因疗法,收益总额超过180万美元,大大降低了他的股权。 Insider Sukumar Nagendran sold over 370,000 shares of Taysha Gene Therapies between September and December 2025, totaling more than $1.8 million in proceeds, reducing his stake significantly. 根据估计,该公司报告每季度每股损失0.09美元,但仍面临负赢利度指标。 The company reported a quarterly loss of $0.09 per share, in line with estimates, but continues to face negative profitability metrics. 12月1日,股票以4.43美元结算,减少0.31美元,交易额低于平均水平。 Shares closed at $4.43 on December 1, down $0.31, with below-average trading volume. 分析师维持了“机动购买”共识,价格目标为10.30美元,尽管有些分析师已将库存降级。 Analysts maintain a "Moderate Buy" consensus with a $10.30 price target, though some have downgraded the stock.